CJC-1295 (DAC)

What It Is

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic GHRH analog that incorporates a maleimidopropionic acid linker enabling covalent binding to circulating albumin. This DAC modification extends the peptide's half-life from approximately 30 minutes (no-DAC) to 6–8 days, producing sustained GH and IGF-1 elevation rather than the pulsatile release pattern of the no-DAC version. In clinical studies, a single subcutaneous injection of CJC-1295 DAC increased mean GH concentrations by 2- to 10-fold for up to 6 days and raised IGF-1 levels by 1.5- to 3-fold for 9–11 days. A Phase II trial enrolling 56 healthy subjects confirmed dose-dependent, sustained elevations in both GH and IGF-1 with once-weekly dosing. The sustained GH elevation produced by the DAC formulation differs fundamentally from natural GH physiology, which relies on discrete pulsatile secretion. This non-pulsatile pattern has raised concerns about potential desensitization of GH receptors and disruption of the normal GH feedback axis with chronic use. Researchers who prefer physiological GH pulsatility typically favor the no-DAC version combined with ipamorelin. CJC-1295 DAC was placed on the FDA's Category 2 list in October 2023. As of May 2026, it remains restricted for 503B outsourcing facilities, though the 503A compounding nomination has been withdrawn. It is classified as a prohibited substance by WADA and is not FDA-approved for any indication.

Why Researchers Study It

CJC-1295 with DAC provides a sustained, non-pulsatile elevation of GH and IGF-1 over days rather than hours. This pharmacokinetic profile makes it a useful research tool for studying the effects of chronic GH elevation versus the pulsatile release pattern produced by the no-DAC variant.

Proposed Mechanisms

• Drug Affinity Complex binds serum albumin, extending half-life to 6–8 days
• Sustained activation of GHRH receptors on pituitary somatotrophs
• Produces continuous GH and IGF-1 elevation rather than pulsatile release
• Less frequent dosing requirement compared to CJC-1295 (no DAC) or sermorelin

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how CJC-1295 (DAC) compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Teichman SL. et al. — Prolonged stimulation of GH and IGF-I by CJC-1295. JCEM. 2006 PubMed

Related Peptides